Sintx Technologies (SINT) Net Cash Flow Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -32.51% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | -87.87% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 42.74% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -11.49% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -87.88% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -48.90% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 129.29% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -65.12% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 33.47% |
| 10 | Sintx Technologies | 8.71 Mn | 6.82 Mn | 144,000.00 | -33.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.03% |
| Dec 31, 2025 | -50.66% |
| Sep 30, 2025 | 38.31% |
| Jun 30, 2025 | 5.77% |
| Mar 31, 2025 | 41.80% |
| Dec 31, 2024 | 25.01% |
| Sep 30, 2024 | 27.06% |
| Jun 30, 2024 | 1.40% |
| Mar 31, 2024 | 48.70% |
| Dec 31, 2023 | -19.04% |
| Sep 30, 2023 | -32.95% |
| Jun 30, 2023 | -32.58% |
| Mar 31, 2023 | -0.44% |
| Dec 31, 2022 | 48.95% |
| Sep 30, 2022 | -123.96% |
| Jun 30, 2022 | -52.02% |
| Mar 31, 2022 | -31.11% |
| Dec 31, 2021 | -25.20% |
| Sep 30, 2021 | -37.34% |
| Jun 30, 2021 | -28.95% |
| Mar 31, 2021 | -81.78% |
| Dec 31, 2020 | 23.61% |
| Sep 30, 2020 | 97.65% |
| Jun 30, 2020 | 69.18% |
| Mar 31, 2020 | 505.47% |
| Dec 31, 2019 | 32.47% |
| Sep 30, 2019 | -27.01% |
| Jun 30, 2019 | 35.68% |
| Mar 31, 2019 | 24.69% |
| Dec 31, 2018 | -106.22% |
| Sep 30, 2018 | -19.92% |
| Jun 30, 2018 | 76.55% |
| Mar 31, 2018 | 54.69% |
| Dec 31, 2017 | -35.42% |
| Sep 30, 2017 | -9.44% |
| Jun 30, 2017 | -26.85% |
| Mar 31, 2017 | -86.18% |
| Dec 31, 2016 | 11.21% |
| Sep 30, 2016 | -5.30% |
| Jun 30, 2016 | -40.14% |
| Mar 31, 2016 | -81.54% |